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Abstract
Introduction: Clinical trials provided controversial results on whether the injection of hyaluronan preparations into
osteoarthritic joints reduces pain. Problems of clinical studies may be the substantial placebo effects of intra-
articular injections, different severity and rate of progression of the disease and others. We hypothesize that the
use of preclinical pain models may help to clarify whether a certain hyaluronan exerts antinociceptive effects upon
intra-articular injection. In the present study we tested in the bradykinin/prostaglandin E2 (PGE2) model primarily
the putative antinociceptive effect of stabilized hyaluronic acid from a non animal source (NASHA), a stabilized
hyaluronic acid based gel for intra-articular treatment of OA. We established a dose-response relationship for
NASHA and we compared NASHA to other hyaluronans with different formulations that are in clinical use.
Methods: To induce transient joint pain episodes bradykinin and PGE2 were repetitively administered intra-articularly
and unilaterally into rat knee joints during short anaesthesia. After establishment of the predrug nociceptive responses,
a single intra-articular injection of saline or NASHA at different concentrations was administered and pain responses to
further bradykinin/PGE2 injections were monitored up to 56 days after NASHA. Furthermore, the obtained effective dose
was compared to clinically defined concentrations of Hylan GF20 and sodium hyaluronate. The primary outcome
measures were primary mechanical hyperalgesia at the knee joint and pain-induced weight bearing.
Results: On day 1 after injection, all tested hyaluronan preparations showed an antinociceptive effect >50%
compared to saline. Single injections of higher doses of NASHA (50, 75 and 100 μl) were antinociceptive up to 56
days. When injection volumes in rat knee joints were adapted to clinical injection volumes in humans, the
antinociceptive effects of the cross-linked NASHA and Hylan GF20 had a longer duration than that of the non
cross-linked sodium hyaluronate (with a slightly better effect of NASHA than Hylan GF20).
Conclusions: In the bradykinin/PGE2 model of joint pain a single injection of all hyaluronan preparations provided
significant antinociceptive effects compared to saline. It appeared that the duration of the antinociceptive effect of the
cross-linked hyaluronan preparations NASHA and Hylan GF20 was more prolonged. In addition, the gel beads structure
allowing only a slow release of hyaluronic acid (NASHA) may even enhance this prolonged antinociceptive effect.
Introduction
Joint pain is among the most frequent chronic pain states
[1]. In most cases, chronic joint pain results from
osteoarthritis (OA), which has a prevalence of about 90%
in the older population [2,3]. At this time OA cannot be
cured. Therefore, symptomatic pain relief is essential
because pain is one of the most disabling symptoms and
can thus cause a significant aggravation of joint dysfunc-
tion [4]. Most often, nonsteroidal anti-inflammatory
drugs (NSAIDs) are clinically used. NSAIDs can effec-
tively reduce inflammation and pain, particularly in exa-
cerbated OA [5], but can also cause significant side
effects such as gastrointestinal and renal disorders [6,7]
when taken regularly. Alternatively, whenever single or
few joints are affected, local antinociceptive therapy
might be considered. In this respect, hyaluronic acid
(HA) preparations are often used. Subject to the prepara-
tion used, HA is injected into the joint one, three, or up
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reported good analgesic effects of HA preparations
[10-13] whereas others found an antinociceptive action
in the range of placebo effects [13,14]. In fact, clinical
trials to prove the efficacy of HA preparations in OA are
compromised by the large placebo effect in this patient
group [15]. The injection of a knee is an active and inva-
sive treatment and hence powerful placebo effects may
mask true antinociceptive effects of compounds. In addi-
tion the tools to record these effects, such as Western
Ontario MacMaster Questionnaire, are subjective in nat-
ure and hence a source of bias. Furthermore, it is impor-
tant which patients are included. For example, one study
included patients with poly-articular OA and knee effu-
sions. For the overall population there was no significant
analgesic effect but when these patients were removed
from the analysis, the stabilised HA was shown to be
highly efficacious over saline in patients with knee OA
[13]. Comprehensive meta-analyses stressed the poor
quality of many trials [16], the heterogeneity among the
studies [17], and came to different conclusions, ranging
from no effect [16], or a small effect, with highest-mole-
cular-weight HA possibly being more efficacious than
lower-molecular weight HA in treating knee OA [17].
The review from Bellamy et al. [18] concludes “overall,
the analyses support the use of the HA class of products
in the treatment of knee OA”. In addition the injection of
different HA preparations at different doses is usually not
feasible.
In this respect, preclinical approaches may provide
important background data on the antinociceptive prop-
erties of HA. For instance, in horses, intraarticular injec-
tions of HA preparations attenuated the lameness in
natural and experimentally induced OA [19,20]. In
anesthetized cats and rodents HA preparations reduced
inflammation- and OA-induced increases of neuronal
discharges in nociceptive Aδ- and C-fibres innervating
the knee joint [21-24]. Herein we show an alternative
preclinical approach to monitor long-term antinocicep-
tive effects of HA preparations, namely the repetitive
induction of short-lasting pain states in the joint by the
injection of bradykinin, combined with prostaglandin E2
(PGE2) [25,26]. These inflammatory mediators sensitize
nociceptive Aδ-and C-fibres to mechanical stimuli
[27-32], a basic mechanism for the occurrence of pain
upon movements in the normal working range of the
joint. Firstly, we validated the described bradykinin/PGE2
model with regards to behavioral readout parameters in
rats for a long-term study on the antinociceptive effects
of stabilized hyaluronic acid from a non-animal source
(NASHA) up to 56 days, and we established a dose-
response relation for NASHA. Secondly, the obtained
effective dose of NASHA was compared with two other
clinically used preparations, that is Hylan GF20 and
sodium hyaluronate, for duration and effect sizes of their
antinociceptive properties.
NASHA is characterized by a gel structure which is
stabilised using about 1% of cross-linking agent, thereby
increasing the half-life time of the product in the joint
compared with traditional HA preparations [33,34].
Thus fewer injections are necessary as compared with
other compounds, which may reduce the risk of infec-
tion [5]. The efficacy of NASHA has been well docu-
mented in clinical studies [35]. Hylan GF20 is another
HA product with a modified HA composition which is
available as an intra-articular formulation for the treat-
m e n to fO A .H e r ew er e p o r to nt h em a g n i t u d ea n d
long-term duration of antinociceptive effects of NASHA
and other HA preparations in the bradykinin/PGE2
model of repetitive joint pain.
Materials and methods
Animals
Female Lewis rats (n = 122, age six to eight weeks,
weight upon arrival 160 to 180 g) supplied by Charles
River (Sulzfeld, Germany) were used. Animals were
housed on a 12:12 hour light:dark cycle with water and
standard rodent chow available ad libitum.A l le x p e r i -
ments were approved by the Thuringian state authorities
(registration numbers 02-045/07 and 02-014/09) and
complied with EC regulations (86/609/EEC). The
Extended Methods Form for uniform reporting stan-
dards in pain-related animal experiments [36] can be
found as an online supplement.
Study design
All intra-articular injections were performed during
short anesthesia with 2% isoflurane (lasting about five
minutes). The assessment of pain-related and locomotor
behavior was started about 30 minutes after isoflurane
application when animals had fully recovered from
anesthesia.
Validation of the bradykinin/PGE2 injection pain model
(protocol 1, n = 12)
Previous models for a short-term induction of pain states
employed intra-articular injections of bradykinin [21]. As
such hyperalgesia lasts for minutes only, we aimed to
prolong this hyperalgesia by simultaneous injection of
PGE2 as described previously [25], which is likewise
known to sensitize afferent fibers [37,38] and which is
released in OA joints. For PGE2 (Cayman Chemical, Ann
A r b o r ,M I ,U S A ) ,ad o s eo f0 . 5μg was used as described
previously [26]. As bradykinin concentrations used in
previously described models vary between 0.03 μga n d
150 μg [25,26,39,40], we aimed at identifying an effective
dose for our purpose, that is a dose that causes a decrease
in mechanical thresholds (see below) of at least 30% last-
ing for at least 90 minutes. For that purpose, we chose an
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0.075, 0.25, 0.75, 2.25, 6.75, 20.25, 60.75, and 182.25 μgo f
bradykinin (Sigma, Deisenhofen, Germany), diluted in
saline together with PGE2 in a total intra-articular injec-
tion volume of 50 μl. The chosen bradykinin concentra-
tion was then verified in four bradykinin-naïve animals.
In order to establish that the model indeed indicates
pain-related behavior, an additional four animals were
treated with morphine (2.5 mg/kg, Sigma, Deisenhofen,
Germany) 30 minutes prior to injection of inflammatory
mediators.
Dose-response relationship for NASHA (protocol 2, n = 77)
For protocol 2 (and 3), sample size calculation including
the estimated effects and known standard deviations in
the pain tests revealed groups of 10 animals. To account
for putative drop-outs, 11 animals were included in all
groups. Similar to the procedures used in clinical stu-
dies, allocation to the respective treatment groups was
randomized and observers were blinded with respect to
the underlying treatment the animals received.
In order to identify an effective anti-hyperalgesic dose of
intra-articularly injected NASHA (Durolane™ 20 mg/ml,
Q-Med AB, Uppsala, Sweden), different volumes of
NASHA (10, 30, 50, 75, and 100 μl, n =1 1p e rg r o u p )
were injected into the left knee joint once. Then, beha-
vioral tests indicating locomotor and pain-related behavior
(see below) were performed on days 1, 7, 14, and 21 after
treatment. Data were compared with those obtained from
animals receiving a single treatment with saline according
to NASHA treatment, or intraperitoneal injections of mor-
phine (2.5 mg/kg; Sigma, Deisenhofen, Germany) on each
testing day, approximately 30 minutes prior to bradykinin/
PGE2 injection. Animals were randomized and group allo-
cation was unblinded at the end of experiments, so except
the morphine-treated animals, observers were unaware of
the respective treatment.
The antinociceptive effect of each NASHA dose was
calculated for each testing day using the mechanical
thresholds (MT) from the injected knee (also see below):
Antinociceptive effectDose = (MTDose − MTsaline)/

MTmorphine − MTsaline

× 100%
Effects were logarithmically plotted against the
NASHA dose used. Linear and sigmoid curves were
fitted using a four parameter logistic function (Origin
8.1G, OriginLabs, USA).
Comparison between different hyaluronic acid preparations
(protocol 3, n = 33)
The following clinically applied HA preparations were
used: NASHA, Hylan GF20 (Synvisc™,G e n z y m eB i o -
surgery, Cambridge, MA, USA) and sodium hyaluronate
(Hyalgan™, Fidia, Padua, Italy). As an injection volume
of 50 μl proved to induce a significant antinociceptive
effect (see results section), injection volumes of the
remaining compounds were adapted according to clini-
cal injection volumes in humans. For NASHA, this is
3 ml, for Hylan GF20 6 ml and for sodium hyaluronate
2 ml, resulting in rat intra-articular injection volumes of
50 μl, 100 μl, and 33 μl, respectively (n = 11 per group).
Again, animals were randomized and unblinding was
performed at the end of experiments. Similar to proto-
col 2, substances were injected intra-articularly once,
and behavioral experiments were performed on days 1,
7, 14, 28, and 56. In order to quantify the antinocicep-
tive effects of the three substances over time, areas
under the curve (AUC) were calculated for saline and
each of the HA preparations. The areas used for ana-
lyses were the integrals over the time points assessed.
These were calculated using the mean of respective dif-
ferences from the baseline value for each group for two
consecutive time points when testing took place, for
example days 1 and 7, multiplied with the number of
days in this interval. The total area was obtained by add-
ing the values from all intervals (1 to 7, 7 to 14, 14 to
28, and 28 to 56). The antinociceptive effect was then
calculated as:
antinociceptive effectCompound =

AUCSaline − AUCCompound

/AUCSaline × 100%
In this calculation, an antinociceptive effect of 0%
means a reduction in thresholds/weight force to the
same extent as saline-treated animals, while 100% would
indicate a complete return to baseline values on all test-
ing days.
Behavioral tests
Assessment of mechanical pain-related behavior
Primary hyperalgesia at the site of the inflamed knee
was assessed using a dynamometer (Correx, Berne, Swit-
zerland) as described previously [41]. In brief, increasing
pressure was applied to the lateral side of the knee joint
at the level of the joint space until the animals
attempted to escape or vocalized. The weight force to
elicit this response was read out in grams. For each ani-
mal and testing day, this test was performed once. To
prevent tissue damage, a cut-off value of 250 g was
defined.
Pain-related guarding behavior of the inflamed hind-
paw was assessed by quantification of weight bearing
towards the non-inflamed hindlimb using an incapaci-
tance tester (Linton Instrumentation, Norfolk, UK).
Here, animals were placed in a plastic cage with both
hindpaws resting on scales. After accommodation to the
device when the animal was sitting calmly, the weight
force resting on the two scales was obtained and aver-
aged during three seconds and values from three conse-
cutive measurements were averaged for every testing
day. From these values, the relative weight (in %) resting
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inflamed hindlimb × 100%/weight on the inflamed + the
non-inflamed hindlimb) as described previously [42].
Secondary, hyperalgesia was assessed at sites remote
from the inflamed joint: the paw and the contralateral
knee joint. Mechanical secondary hyperalgesia at the
contralateral knee joint was assessed according to the
description given for the inflamed knee above. In addi-
tion, secondary mechanical hyperalgesia was obtained
from the paw using a dynamic plantar aesthesiometer
(Ugo Basile, Comerio, Italy) as previously described [43].
In brief, a blunt filament touches against the paw with
increasing pressure (2.5 g/s, cut-off 50 g) until the ani-
mal withdraws, and the weight force needed to elicit
this response is read out in grams. Measurements were
taken in triplicate.
Locomotor behavior
To test for dynamic motor behavior and locomotor
coordination, animals were tested on an accelerating
RotoRod device (IITC Instruments, CA, USA). Animals
were placed on a drum with 8 cm in diameter that
started to rotate in an accelerating fashion, increasing
from 4 to 40 rpm in 300 second. The speed at which
t h ea n i m a lb e c a m eu n a b l et os t a yo nt h ed r u mw a s
obtained and used as readout parameter.
In addition, a guarding score was assessed as described
previously [44]: 0: no guarding, 1: guarding of the hin-
dlimb after a defined brief noxious compression of the
knee, 2: visible limping during walking without previous
pain stimulus, 3: no use of the hindlimb with the arthritic
k n e e ,4 :n om o v e m e n ta ta l l( g e n e r a lm o r b i d i t y ) .
Statistical analyses
For statistical analyses, SPSS for windows (version 17.0)
was used. First, data were tested for normal distribution
applying Kolmogorov-Smirnov tests. For protocol 1, differ-
ent doses were compared with baseline values using paired
two-sided t-tests applying Bonferroni-Holm correction for
multiple comparisons. For protocols 2 and 3, the measures
obtained from different time points were compared
between groups using repeated measures analysis of var-
iances (ANOVAs) with the between-subjects factor Group
(NASHA doses of 10, 30, 50, 75, and 100 μl for protocol 2;
NASHA, Hylan GF20 and sodium hyaluronate for proto-
col 3) and the within-subjects factor Time (baseline, days
1, 7, 14, and 21 after initiation of treatment for protocol 2,
and baseline, days 1, 7, 14, 28, and 56 for protocol 3).
Antinociceptive effects over time (protocol 3) were com-
pared between groups using one-way ANOVAs. Post-hoc
t-tests were performed to describe differences between
groups at different time points whenever ANOVAs
revealed significant overall effects. For protocol 2, only
injection volumes 10, 50, and 100 μl were compared in
post-hoc tests in order to avoid multiple comparisons.
F-values from multivariate tests are presented in the text,
while P values from post-hoc t-tests are displayed in the
figures and tables. Significance was accepted for P < 0.05.
Results
Validation of the bradykinin/PGE2 pain model (Protocol 1)
Injection of 0.5 μgP G E 2 together with different concen-
trations of bradykinin led to a decrease in mechanical
thresholds. For doses up to 0.25 μg of bradykinin, this
effect was smaller than the desired 30% reduction (corre-
sponding to a weight force of 175 g in the mechanical
threshold testing). Starting from 0.75 μg of bradykinin;
however, a significant decrease below 175 g assessed 120
minutes after injection was obtained (Figure 1a). Injec-
tion concentrations of 0.25 μgo fb r a d y k i n i no rh i g h e r
further induced transient licking of the injection side. In
addition, concentrations between 0.25 and 2.25 μg caused
limping upon defined noxious stimulation (according to a
score of ‘1’) for about 15 to 20 minutes, while concentra-
tions of 6.75 μg and higher mainly caused visible limping
without prior stimulation (according to a score of ‘2’)f o r
about the same time. Besides primary mechanical hyper-
algesia, animals showed pronounced and statistically sig-
nificant weight bearing starting from 22.25 μg bradykinin
(Figure 1b).
As no adverse effects were observed up to a concen-
tration of 182.25 μg, and as at this concentration all
parameters indicating pain, that is a decrease in thresh-
olds, a significant weight shifting, licking, and limping
could be observed reliably, this dose was chosen and
used in an additional four animals that had not received
any other bradykinin/PGE2 i n j e c t i o nb e f o r ei no r d e rt o
verify the effect in naïve animals (Figure 1).
Application of morphine 30 minutes prior to bradyki-
nin/PGE2 injection completely abolished the hypernoci-
ceptive effect as assessed using mechanical thresholds
and weight bearing, thereby confirming that the mea-
sures obtained indeed indicate pain (Figure 1).
Dose response relationship for NASHA regarding pain-
related behavior (protocol 2)
Repeated measures ANOVAs showed significant Time ×
Group interactions for primary mechanical hyperalgesia
assessed as mechanical thresholds at the injected knee
joint (F(16,141) = 1.947; P = 0.021) and for weight bearing
as obtained from incapacitance testing (F(16,141) = 1.798;
P =0 . 0 4 2 ) .R e s u l t sf r o mpost-hoc t-tests are displayed in
Figure 2. Here, the lower application volumes of 10 and
30 μl showed a rather linear decrease in MTs during the
observation period of 21 days, while the higher volumes
administered remained close to baseline levels and
morphine treatment (Figure 2a). For weight bearing, a
similar effect was observed, with more pain-related weight
shifting in animals receiving the low doses (Figure 2b). No
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algesia (data not shown) or in locomotor coordination
(F = 1.174; P = 0.296).
For each testing day, antinociceptive effects were
plotted against the administered volume of NASHA
(Figure 3). From this, it becomes obvious that all con-
centrations used show an antinociceptive effect of
more than 50% on day 1 (Figure 3a), but that the low
concentrations used (10 μla n d3 0μl) show a decline
in efficacy over time (Figures 3b to 3d), while the
higher injection volumes remain rather stable at effects
above 50%.
Figure 1 Induction of transient pain by co-injection of PGE2
(0.5 μg) and bradykinin at different concentrations. (a) Primary
mechanical hyperalgesia as assessed by ascending pressure applied
to the knee joint. Here, the desired drop in mechanical thresholds
from baseline (BL) of more than 30% was obvious starting from 0.75
μg bradykinin in an escalating dose design (n = 4). For the chosen
dose of 182.25 μg, this was verified in bradykinin-naïve animals (n =
4). Furthermore, the pain-related behavior induced by this
concentration could be reversed by morphine (Mo; n = 4). (b)
Weight force on the injected hindpaw (as percentage of total
weight on both hindpaws). Here, a significant effect was obvious for
concentrations of 22.25 μg and higher. Again, this effect could be
verified in bradykinin-naïve animals and morphine administration
prevented weight shifting. Data are presented as mean ± standard
error of the mean. * P < 0.05 as obtained using t-tests applying
Bonferroni-Holm correction. PGE2, prostaglandin E2.
Figure 2 Time course of the antinociceptive effects upon a
single intra-articular injection of different NASHA doses. (a)
Primary mechanical hyperalgesia at the knee joint as assessed by
measuring the mechanical threshold upon ascending pressure
applied to the knee joint. NASHA doses were 10, 30, 50, 75, and 100
μl (each n = 11, except 30 μl, n = 10). Here, the lower doses used, 10
and 30 μl injection volumes, showed a linear decrease, while the
higher doses did not significantly differ from baseline (BL) levels. (b)
Weight force on the injected hindpaw (as percentage of total weight
on both hindpaws). Same doses as in a. The effects were similar, yet
less clear-cut than those obtained from mechanical thresholds, but
verified a shorter-lasting and smaller efficacy of the lower doses. Data
are presented as mean ± standard error of the mean. + comparison
between NASHA 10 and NASHA 100; * comparison between NASHA
10 and NASHA 50; § comparison between NASHA 50 and NASHA
100. One symbol: P < 0.05; two symbols: P < 0.01 as obtained from
descriptive t-tests following repeated measures analysis of variances.
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interpolation showed that neither of the two relations
sufficiently described the dose-response relation, but
that rather a certain amount of NASHA needs to be
administered in order to achieve an antinociceptive
effect. This threshold dose lies between 30 and 50 μl
injection volume. For day 14, only a linear fit could be
calculated (Figure 3c).
Comparison between clinically used HA formulations
(protocol 3)
As an injection volume of 50 μl proved to induce a signifi-
cant antinociceptive effect (see results section), injection
volumes of the remaining compounds were adapted
according to clinical injection volumes in humans. For
NASHA, this is 3 ml, for Hylan GF20 6 ml and for sodium
hyaluronate 2 ml, resulting in rat intra-articular injection
volumes of 50, 100, and 33 μl, respectively (n =1 1p e r
group). Repeated measures ANOVAs showed significant
Time × Group interactions for primary mechanical hyper-
algesia (F(15,94) = 3.550; P < 0.001) and weight bearing
(F(15,94) = 2.646; P = 0.002). In particular, MTs at the
injected knee were significantly higher in NASHA-treated
animals than in sodium hyaluronate-treated animals on
days 7 and 56 after injection (Figure 4a). The antinocicep-
tive effect over time using AUC analyses for this para-
meter was significantly different between groups (F =
5.630; P = 0.009, Figure 4b). For weight bearing, animals
Figure 3 Dose-response relation for NASHA regarding antinociceptive effects on different days. (a to d) Increase in thresholds in relation
to saline (0%) and morphine (100%) on days 1, 7, 14, and 21 after injection. Overall, only the higher doses (50, 75, and 100 μl, each n = 11)
show an antinociceptive effect of more than 50% beyond day 1, but not 10 and 30 μl( n = 11 and n = 10, respectively). Fitting of linear and
sigmoid curves (only linear fitting was possible for day 14) revealed no clear-cut relation, but apparently a certain threshold dose is needed to
obtain antinociceptive effects. Data are presented as mean ± standard error of the mean.
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mechanical hyperalgesia as assessed by ascending pressure applied to the knee joint, after injection of NASHA (50 μl, n = 11), Hylan GF20 (100
μl, n = 9), and sodium hyaluronate (33 μl, n = 11). Although saline-treated animals showed a dramatic drop in mechanical thresholds from day
1, all hyaluronic acid compounds showed antinociceptive properties. These were most pronounced for NASHA and Hylan GF20, which were
superior to sodium hyaluronate, particularly in the later stages. (b) When calculating the area under the curve (AUC) in order to quantify the
antinociceptive effects of these substances (baseline curve - saline curve), NASHA showed a significantly stronger effect than sodium
hyaluronate, whereas only a trend was observed in comparison with Hylan GF20. (c) Weight force on the injected hindpaw (as percentage of
total weight on both hindpaws). Same dosing as in a. Here, a similar pattern was obvious, with particularly sodium hyaluronate losing efficacy
from day 7 after injection, while NASHA, and to a lesser degree Hylan GF20, maintained weight-bearing behavior close to baseline levels. (d)
Calculation of the respective antinociceptive effects for this parameter showed significant differences between NASHA and Hylan GF20 as well as
between NASHA and sodium hyaluronate. Data are presented as mean ± standard error of the mean. (a and c) + comparison between NASHA
and Hylan GF20. * comparison between NASHA and sodium hyaluronate. § comparison between Hylan GF20 and sodium hyaluronate. One
symbol: P < 0.05; two symbols: P < 0.01 as obtained from descriptive t-tests following repeated measures analysis of variances (ANOVAs). (b and
d) * P < 0.05; ** P < 0.01 as obtained from descriptive t-tests following one-way ANOVAs.
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particularly on the late observation days (Figure 4c). Here,
the overall antinociceptive effects showed an even stronger
differentiation between groups (F = 11.178; P < 0.001) with
NASHA being slightly more effective than Hylan GF20
and strongly more antinociceptive than sodium hyaluro-
nate (Figure 4d).
Secondary mechanical hyperalgesia as assessed at the
contralateral knee (F = 0.837; P = 0.634) or at the ipsi- and
contralateral paws (F = 0.993; P = 0.469 and F = 0.789; P =
0.693, respectively) was not different between treatment
groups. Furthermore, there were no differences in locomo-
tor coordination as assessed using the RotoRod device (F =
0.604; P = 0.865).
Discussion
In the present study, we were able to validate the antino-
ciceptive effects of HA preparations in a highly reprodu-
cible animal pain model using repeated intra-articular
injections of bradykinin and PGE2.I nt h i sm o d e lw e
established a dose-response relation for the HA formula-
tion of NASHA, showing that smaller injection volumes
provided a weaker and shorter lasting effect than higher
volumes. In addition, using clinically administered injec-
tion volumes in humans as a reference, NASHA was
compared with different HA formulations, that is Hylan
GF20 and sodium hyaluronate, with regards to pain-
related and locomotor behavior. Overall, in the first days
after injection all the HA preparations showed antinoci-
ceptive effects over that of intra-articular injection of sal-
ine, negative control. However, particularly in the long-
term range the effectiveness of the tested HA products
differed, with NASHA having the strongest antinocicep-
tive action, followed by Hylan GF20, then sodium hyalur-
onate, under the conditions of these experiments.
Use of the bradykinin/PGE2 model for the study of HA
effects (protocol 1)
Intra-articular injection of bradykinin and PGE2 led to a
reproducible, repeatedly applicable and significant
change in pain-related behavior as assessed employing
different methods (see effects of saline and morphine
injections). Although in principle, such models, mainly
using bradykinin alone, have been used before [25,26],
we could now validate this model for the assessment of
long-lasting antinociceptive effects of a single injection
of HA preparations in individual animals. In previous
studies the antinociceptive effects of a HA preparation
were assessed for a maximum of 96 hours, and bradyki-
nin was only injected once [25]. It is particularly worth
mentioning that repeated applications of bradykinin and
PGE2 did not induce tachyphylaxia in this design, and
that the anticipated effect of a reduction in mechanical
thresholds of more than 30% was present on all testing
days up to week 7.
The employed pain model does not reflect all aspects
of clinical OA or other joint diseases. It should be
noted, however, that there is no consensus in pain
research which model is most suitable to study OA
pain. This also reflects the clinical situation. So far the
pain mechanisms of OA are not well understood. How-
ever, the model provides a rather reliable, fast, and effi-
cient way to address the antinociceptive effects of single
injections of HA preparations in a long-term design per
se. It may mimic pain conditions at a stage of OA,
which evokes episodically moderate pain and does not
r e q u i r et h eu s eo fs t r o n ga n a l g e s i c so rs y s t e m i cp a i n
treatment. An advantage is that the effects observed
herein can be attributed directly to the antinociceptive
effects of HA rather than to disease modification.
Finally, the protocol of repetitive induction of short-last-
ing pain states limits suffering of experimental animals.
Pain is totally avoided when nerve fibres are recorded in
anesthetized animals [21-24], but in these experiments
measurements are usually restricted to one day (or time
point) only.
Dose-response relationship of NASHA (protocol 2)
In order to obtain quantitative data on the dose-response
relation with regards to pain-related behavior, five differ-
ent doses of NASHA were administered. As NASHA con-
sists of a fixed chemical structure, the dosing is established
by injecting different volumes into the knee joint. When
looking at previous studies and animal models employing
knee joint injections, a volume of 50 μla p p e a r e dt ob e
mostly used [25,26,39,45,46] and - considering joint
volumes between species - comparable with respective
injection volumes in humans. From this, two larger and
two smaller doses were chosen. Dose-dependently, these
injection volumes reduced pain-related behavior, as
reflected in an attenuated decrease of MTs upon bradyki-
nin/PGE2 injections and in a normalization of the weight
shift seen in saline-treated control animals. The antinoci-
ceptive effects of doses of 50 to 100 μl were similar as
those obtained with morphine. Importantly, doses of 50 μl
or more had an antinociceptive effect throughout the
observation period of 56 days.
The original aim of this design was to establish a loga-
rithmic curve, from which ED50 values might be obtained.
From the data, however, no clear-cut sigmoid or linear
relation could be established. Rather, there appears to be a
certain threshold dose or volume that needs to be injected
in order to achieve therapeutic effects, which, in our study,
lies between 30 and 50 μl. Only the higher doses yielded
persistent effects up to 56 days. An additional increase of
injection volumes did not result in dramatically stronger
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tion period in this study.
Putative mechanisms of hyaluronic acid effects
The mechanisms underlying the beneficial effects of HA
in OA pain/degenerative pain are not completely under-
stood to date. As putative modes of action, the viscous
properties of the substances have been discussed, acting
as a mechanical protection for the joint. Furthermore,
due to the texture of the respective preparations, HA
might be capable of covering sensory endings that can
then no longer be sensitized by inflammatory mediators
[24]. Alternatively, these mediators which also include
those used in our model to induce the acute pain states,
that is bradykinin and PGE2, might be entrapped in the
viscous compound, thereby being unable to reach the
respective receptors in sufficient concentration. Indeed,
some preliminary work has indicated that NASHA can
bind and hold bradykinin possibly through electrostatic
interaction (data not shown). Besides that, HA repre-
sents, under healthy conditions, the major component of
synovial fluid and fulfils important trophic-metabolic
functions [47-49]. Irrespective of the exact mechanism,
recordings from afferent nociceptive fibers in anesthe-
tized animals showed reduced excitability upon intra-
articular treatment with HA [21-24]. Ultimately, only
deeper insights in of these mechanisms will allow the
understanding of the threshold effect described here.
Comparison between hyaluronic acid preparations
(protocol 3)
For comparison of the antinociceptive effects of different
compounds we adapted the volumes of the preparations
according to clinical injection volumes in humans (see
Results). Furthermore, we took into account that for the
injection of the rat knee joint a volume of 50 μli sm o s t
suitable (and has hence been routinely used for studies,
see above) whereas an OA human knee volume was
estimated to be more than 3 ml [50]. Thus, with 50 μl
NASHA we achieved a similar 1:1 ratio between the
injected volume and the physiological joint space as
when 3 ml NASHA (the usually applied dose) are
injected into a human knee joint. Under these condi-
tions, NASHA showed the strongest antinociceptive
effects, followed by Hylan GF20, while sodium hyaluro-
nate - despite showing good efficacy in the very early
testing days - was less potent, particularly in the late
stages of the observation period. For almost all mechan-
isms discussed for the effects of HA in degenerative
joint disease mentioned above, it appears to be of major
importance for how long the substance can actually
remain in the joint cavity before being washed out. In
that respect, NASHA and Hylan GF20, the two longer-
lasting and more effective substances, have in common
that they are cross-linked and thereby less likely to be
cleared from the joint as rapidly as the non-cross-linked
sodium hyaluronate. The even stronger effect of
NASHA might therefore be caused by the chemical
structure of gel beads that release the HA more slowly,
and the gel nature of this preparation preventing an
early washout. In addition, different half life times of the
compounds were reported. For unmodified hyaluronan
like sodium hyaluronate, this is 12 to 24 hours [51], for
Hylan GF20 approximately up to 8.8 days [52], and for
NASHA 28 to 32 days [33,34], thereby possibly adding
to the explanation of the longer-lasting effect of the
latter.
Limitations and advantages
The comparison between substances was performed by
establishing a dose-response relation for NASHA, and cal-
culating the injection volumes of the compared substances
according to clinically used amounts. Therefore, the abso-
lute amounts of HA injected differ between substances.
Particularly, the least effective substance, that is sodium
hyaluronate, was injected in a rather small volume only
(corresponding, however, to the clinically injected volume,
see above), thereby putatively confounding our results.
Furthermore, sodium hyaluronate is an unmodified hya-
luronan, which has the shortest half-life time (see above)
and is rapidly removed from the joint space and therefore
needs to be re-injected three to five time in weekly inter-
vals. This might also explain the rather weak effect of this
substance in the model used. Pointing in the same direc-
tion, in recordings from nerve fibers of joints, sodium hya-
luronate did not reduce the discharges of the nerve fibres
whereas in the same experimental setting Hylan GF20
reduced the impulse frequency [22].
As different compounds were compared in the present
study and in order to reduce any bias due to expecta-
tions, we applied a group size estimation, randomiza-
tion, and blinding process which is usually only used in
clinical studies, thereby increasing internal validity [53]
and adding value to the results shown here.
Conclusions
The injection of HA preparations into OA joints is often
used to treat OA pain. However, the assessment of the
antinociceptive effects of HA preparations solely from
human studies is difficult for several reasons, namely the
strong placebo effect upon intra-articular injection, the
long duration of the observation period (eventually with
disease progression), the difficulty to test different doses
of one compound, and the difficulty to compare different
HA preparations. The present study shows that long-
term antinociceptive effects of HA preparations can be
assessed in an animal model of joint pain based on the
repeated intra-articular injection of bradykinin and PGE2.
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causes a transient short-lasting joint pain state, and upon
repeated injections this pain induction is reproducible
over weeks. In this pain model, a single injection of 50 μl
of NASHA and higher into the knee joint led to a nor-
malization of pain-related behavior close to baseline
levels during an observation period of seven weeks.
When injection volumes in rat knee joints were adapted
to clinical injection volumes in humans, NASHA showed
slightly better antinociceptive effects than Hylan GF20,
and both substances were superior to sodium
hyaluronate.
Overall, this study has demonstrated that all tested
HA preparations are effective in providing pain relief
when injected into the joint. Remarkably, NASHA and
Hylan GF20 (as Synvisc™ One) are the only products
t h a ta r ec u r r e n t l ya v a i l a b l ea ss i n g l ei n j e c t i o n s .I nt h e
pain model employed in the present study, NASHA pro-
vided the best prolonged antinociceptive effect upon a
single intra-articular injection.
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